Examples of using Rienso in English and their translations into Croatian
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
adverse reactions were seen in 7.9% of patients who received Rienso, of which 0.2% were considered serious.
In the 24 hours following administration of Rienso, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in the Rienso complex.
Three main studies involving 838 chronic kidney disease patients with iron deficiency anaemia have been carried out to compare Rienso with an iron treatment taken by mouth.
Rienso must not be mixed with other medicinal products, with the exception of the infusion fluids mentioned below.
Your doctor will decide how much Rienso to give you based on your weight and blood test results.
Rienso must not be used in people with a history of drug allergy,
Rienso should only be given when healthcare professionals trained to manage anaphylactic(severe allergic)
Hypotension may follow Rienso administration with or without accompanying signs of hypersensitivity see section 4.8.
Rienso will be administered in an environment where any allergic event can receive appropriate and prompt treatment.
In studies with Rienso, side effects were seen in 7.9% of patients taking the medicine, of which 0.2% were considered serious.
Administer Rienso as an infusion as follows:
In all three studies, patients taking Rienso had higher average increases in haemoglobin: 1.2 g/dl versus 0.5 g/dl;
receive two additional 510 mg intravenous injections of Rienso for a total cumulative dose of 2.04 g.
general reproductive performance were noted in rats given IV Rienso at doses up to 18 mg Fe/kg/day Human Equivalent Dose of 2.9 mg Fe/kg/day.
transferrin bound iron by also measuring the iron in Rienso.
Rienso is used to treat anaemia(low levels of red blood cells
Rienso must only be mixed with sterile sodium chloride 9 mg/ml(0.9%)
Rienso should be administered as an infusion in 50-250 ml of sterile 0.9% sodium chloride
Rienso should only be administered when staff trained to evaluate
case per 100 patients) and were reported in 0.2%(3/1562) of subjects with CKD who received Rienso during the clinical studies.